Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the respiratory community has seen a continuous growth in the number of biologics ...

In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

a firm specialising in injectable drugs and biosimilars, at a time when copycat biologics were starting to make real waves in the market. The deal seemed to be a precursor to Pfizer's plans to ...

FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ask for funding.

In fact, the success of biosimilars in Europe has given the United ... UnitedHealthcare announced preferred formulary status for Pfizer’s Retacrit, Amgen’s Mvasi, and Amgen’s Kanjinti.

The global sales of eye infections treatment is estimated to be worth USD 8,125.2 million in 2025 and anticipated to reach a value of USD 11,890.2 million by 2035. Sales are projected to rise at a ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...